Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Anand, Prachi ^a,b   O'Neil, Alison ^c   Lin, Emily ^a   Douglas, Trevor ^c   Holford, Mandë ^a,b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b DIVISION OF INVERTEBRATE ZOOLOGY   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; NANOCOMPOSITE; OMEGA CONOTOXIN; OMEGA CONOTOXIN MVIIA; RAB PROTEIN; RAB11 PROTEIN; TRANSACTIVATOR PROTEIN;

AMINO ACID SEQUENCE; ANIMAL; BLOOD BRAIN BARRIER; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENDOTHELIUM CELL; ENTEROBACTERIA PHAGE P22; HUMAN; METABOLISM; MOLECULAR GENETICS; RAT; VASCULAR ENDOTHELIUM; VIRUS CAPSID;

AMINO ACID SEQUENCE; ANALGESICS, NON-NARCOTIC; ANIMALS; BACTERIOPHAGE P22; BLOOD-BRAIN BARRIER; CAPSID; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MOLECULAR SEQUENCE DATA; NANOCOMPOSITES; OMEGA-CONOTOXINS; RAB GTP-BINDING PROTEINS; RATS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84938524946     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12497     Document Type: Article

References (46)

1. Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R. & Begley, D. J. Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13-25 (2010).
2. Zlokovic, B. V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201 (2008).
3. Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2, 3-14 (2005).
4. Fleige, E., Quadir, M. a & Haag, R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv. Drug Deliv. Rev. 64, 866-884 (2012).
5. Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).
6. De, M., Ghosh, P. S. & Rotello, V. M. Applications of Nanoparticles in Biology. Adv. Mater. 20, 4225-4241 (2008).
7. Halaia, R. & Craik, D. J. Conotoxins: natural product drug leads. Nat. Prod. Rep. 26, 526-536 (2009).
8. Terlau, H. & Olivera, B. M. Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol. Rev. 84, 41-68 (2004).
9. Olivera, B. M. Conus venom peptides: reflections from the biology of clades and species. Annu. Rev. Ecol. Syst. 33, 25-42 (2002).
10. Puillandre, N. & Holford, M. The Terebridae and teretoxins: combining phylogeny and anatomy for concerted discovery of bioactive compounds. BMC Chem. Biol. 10, 7 (2010).
11. Gonzales, D. T. T. & Saloma, C. P. A bioinformatics survey for conotoxin-like sequences in three turrid snail venom duct transcriptomes. Toxicon 92, 66-74 (2014).
12. Miljanich, G. P. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 11, 3029-3040 (2004).
13. McGivern, J. G. Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr. Dis. Treat. 3, 69-85 (2007).
14. Droney, J. M. et al. Analgesia and central side-effects: two separate dimensions of morphine response. Br. J. Clin. Pharmacol. 75, 1340-1350 (2013).
15. Dworkin, R. H. et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132, 237-251 (2007).
16. Attal, N. et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol. 17, 1113-e88 (2010).
17. Lewis, R. J. Conotoxins: molecular and therapeutic targets. Prog. Mol. Subcell. Biol. 46, 45-65 (2009).
18. Han, T. S., Teichert, R. W., Olivera, B. M. & Bulaj, G. Conus venoms - a rich source of peptide-based therapeutics. Curr. Pharm. Des. 14, 2462-2479 (2008).
19. Essack, M., Bajic, V. B. & Archer, J. a C. Conotoxins that confer therapeutic possibilities. Mar. Drugs 10, 1244-1265 (2012).
20. Clark, R. J. et al. Engineering stable peptide toxins by means of backbone cyclization: stabilization of the alpha-conotoxin MII. Proc. Natl. Acad. Sci. USA. 102, 13767-13772 (2005).
21. Lovelace, E. S. et al. Cyclic MrIA: a stable and potent cyclic conotoxin with a novel topological fold that targets the norepinephrine transporter. J. Med. Chem. 49, 6561-6568 (2006).
22. Blanchfield, J. T. et al. Oral absorption and in vivo biodistribution of alpha-conotoxin MII and a lipidic analogue. Biochem. Biophys. Res. Commun. 361, 97-102 (2007).
23. Clark, R. J. et al. The engineering of an orally active conotoxin for the treatment of neuropathic pain. Angew. Chem. Int. Ed. Engl. 49, 6545-6548 (2010).
24. Staats, P. S. et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. J. Am. Med. Assoc. 291, 63-70 (2004).
25. Tian, X. et al. Blood-brain barrier transport of Tat peptide and polyethylene glycol decorated gelatin-siloxane nanoparticle. Mater. Lett. 68, 94-96 (2012).
26. Wei, B. et al. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide. Biomed. Pharmacother. 63, 313-318 (2009).
27. Liu, L. et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials 29, 1509-1517 (2008).
28. O'Neil, A., Reichhardt, C., Johnson, B., Prevelige, P. E. & Douglas, T. Genetically programmed in vivo packaging of protein cargo and its controlled release from bacteriophage P22. Angew. Chem. Int. Ed. Engl. 50, 7425-7428 (2011).
29. Steiner, A. M. & Bulaj, G. Optimization of oxidative folding methods for cysteine-rich peptides: a study of conotoxins containing three disulfide bridges. J. Pept. Sci. 17, 1-7 (2011).
30. Yang, Z.-H. et al. An in vitro transport model for rapid screening and predicting the permeability of candidate compounds at blood-brain barrier. J. Asian Nat. Prod. Res. 13, 1087-1097 (2011).
31. Roux, F. & Couraud, P.-O. Rat Brain Endothelial Cell Lines for the Study of Blood-Brain Barrier Permeability and Transport Functions. Cell. Mol. Neurobiol. 25, 41-57 (2005).
32. Terryn, C. et al. Rapid method of quantification of tight-junction organization using image analysis. Cytometry. A 83, 235-241 (2013).
33. Rodgers, L. S., Beam, M. T., Anderson, J. M. & Fanning, A. S. Epithelial barrier assembly requires coordinated activity of multiple domains of the tight junction protein ZO-1. J. Cell Sci. 126, 1565-1575 (2013).
34. Yu, P.-F. et al. The Role of P-Glycoprotein in Transport of Danshensu across the Blood-Brain Barrier. Evid. Based. Complement. Alternat. Med. 2011, 713523 (2011).
35. Fromm, M. F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25, 423-429 (2004).
36. Sancini, G. et al. Functionalization with TAT-Peptide Enhances Blood-Brain Barrier Crossing In vitro of Nanoliposomes Carrying a Curcumin-Derivative to Bind Amyloid-β Peptide. J. Nanomed. Nanotechnol. 4, 171 (2013).
37. Yang, Z.-H., Sun, X., Mei, C. & Al, E. An in vitro transport model for rapid screening and predicting the permeability of candidate compounds at blood - brain barrier. J. Asian Nat. Prod. Res. 13, 1087-1097 (2011).
38. Rempe, R., Cramer, S., Hüwel, S. & Galla, H.-J. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. Biochem. Biophys. Res. Commun. 406, 64-69 (2011).
39. Thomsen, L. B. et al. Uptake and transport of superparamagnetic iron oxide nanoparticles through human brain capillary endothelial cells. ACS Chem. Neurosci. 4, 1352-1360 (2013).
40. Tünnemann, G. et al. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J. 20, 1775-1784 (2006).
41. Tamai, I. et al. Structure-internalization relationship for absorptive-mediated endocytosis of basic peptides at the blood-brain barrier. J. Pharmacol. Exp. Ther. 280, 410-415 (1997).
42. Hervé, F., Ghinea, N. & Scherrmann, J.-M. CNS delivery via adsorptive transcytosis. AAPS J. 10, 455-472 (2008).
43. Heuser, J. E. & Anderson, R. G. Hypertonic media inhibit receptor-mediated endocytosis by blocking clathrin-coated pit formation. J. Cell Biol. 108, 389-400 (1989).
44. Takahashi, S. et al. Rab11 regulates exocytosis of recycling vesicles at the plasma membrane. J. Cell Sci. 125, 4049-4057 (2012).
45. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63 (1983).
46. Yildiz, I., Shukla, S. & Steinmetz, N. F. Applications of viral nanoparticles in medicine. Curr. Opin. Biotechnol. 22, 901-908 (2011).